ABSTRACT BACKGROUND Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with
Numerous studies have demonstrated the safety and efficacy of TAVR, and more than 250,000 patients have been treated with this technology (1) (2) (3) (4) (5) (6) . Although randomized trials have established TAVR as the standard treatment in inoperable patients and a reasonable option in high surgical-risk patients, these trials excluded congenital bicuspid AS due to its unique morphological features (1,2,5-7).
The experience of TAVR in bicuspid AS is limited to small series (8) (9) (10) (11) (12) . Based on data from previous registries, the proportion of patients with bicuspid AS may reach 2% to 6% (13, 14) . Previous studies were limited by the clear baseline differences in age and comorbidities favoring the bicuspid AS study group In the unadjusted cohort, patients with bicuspid AS were younger and more likely to be male, whereas patients with tricuspid AS were more likely to have multiple comorbidities (Online Table 1 14.5%; p < 0.001), whereas the transfemoral approach was equally frequent in both groups. After performing propensity score matching, both groups were well matched, with no significant differences in baseline characteristics, except more frequent use of the largest prostheses in the bicuspid AS group (Table 1) .
PROCEDURAL AND CLINICAL OUTCOMES. In terms of 30-day clinical outcomes, there were no significant differences between the bicuspid In terms of outcomes across bicuspid phenotype, there were no significant differences in procedural and clinical outcomes between type 0 and type 1 bicuspid AS (Online Table 2 ). Of note, moderate or severe paravalvular leak occurred in 5 patients (Figures 3A and 3B ). These findings were consistently observed in propensity scorematched cohorts for early-and new-generation devices (Online Figures 6A and 6B) .
DISCUSSION
The present study is the first large-scale study to compare the safety, efficacy, and clinical outcomes of TAVR in patients with bicuspid and tricuspid AS. The major findings of the present study are as follows:
1. In the propensity score-matched cohort, TAVR in patients with bicuspid AS was associated with more frequent adverse procedural events compared with those with tricuspid AS. These differences were observed among patients treated with the early-generation devices. Values are n (%) or mean AE SD, unless otherwise indicated.
CI ¼ confidence interval; OR ¼ odds ratio; other abbreviations as in Table 1 .
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2. However, there were no significant differences in procedural complications between groups when using the new-generation devices. In the present study, compared with tricuspid AS, TAVR in bicuspid AS was associated with similar Cumulative all-cause mortality rates in patients with bicuspid AS (orange) and tricuspid AS (blue) in a propensity score matched cohort. Event rates were compared using the win ratio test. AS ¼ aortic valve stenosis.
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New-Generation Devices
Cumulative all-cause mortality rates in patients with bicuspid AS (orange) and tricuspid AS (blue) treated with (A) early-and (B) newgeneration devices, respectively. Event rates were compared using the log-rank test. STUDY LIMITATIONS. First, this study had the inherent limitations of an observational study without center-independent adjunction of adverse events and an independent core laboratory to diagnose bicuspid AS and assess paravalvular leak.
Moreover, although propensity score matching is a well-accepted approach in observational research to address differences in baseline characteristics, it cannot account for unmeasured bias. Last, device selection was not randomized, but was at the operator's discretion, and patient selection as well as operator experience may have affected the observed outcomes.
CONCLUSIONS
Compared with tricuspid AS, TAVR in bicuspid AS was associated with a similar prognosis, but a lower device success rate. Procedural differences were observed in patients treated with the earlygeneration devices, whereas no differences were observed with the new-generation devices. 
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